Sinus node dysfunction and sudden cardiac death following treatment with encainide.
Encainide, a class Ic drug, is generally thought of as having little effect on sinus node function. In this article, we present the clinical course and electrophysiological findings of a patient who had cardiac arrest after 1 week of encainide therapy for ventricular extrasystoles. No ventricular tachyarrhythmias were induced during programmed ventricular stimulation (baseline study and while receiving encainide therapy). Prior to encainide therapy, sinus node function was normal, but clinical observations after admission for cardiac arrest and subsequent electrophysiological study revealed that encainide had caused striking impairments in sinus node function. During a 6-month follow-up without antiarrhythmic drug treatment, this patient has had an uneventful course. We concluded that encainide can cause severe and life-threatening sinus node dysfunction.
Lemery
R
R
Department of Medicine, Montreal Heart Institute, Quebec, Canada.
Talajic
M
M
Nattel
S
S
Theroux
P
P
Roy
D
D
D000813:Anilides / Q000009:adverse effects* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001146:Arrhythmia, Sinus / Q000139:chemically induced*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D002304:Cardiac Pacing, Artificial; D003645:Death, Sudden / Q000209:etiology*; D004562:Electrocardiography; D004594:Electrophysiology; D016700:Encainide; D005260:Female; D006323:Heart Arrest / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D016700:Encainide